{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:24:38Z","timestamp":1790717078941,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"27","license":[{"start":{"date-parts":[[2010,5,10]],"date-time":"2010-05-10T00:00:00Z","timestamp":1273449600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2010,5,10]],"date-time":"2010-05-10T00:00:00Z","timestamp":1273449600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2010,7,8]]},"DOI":"10.1038\/onc.2010.145","type":"journal-article","created":{"date-parts":[[2010,5,10]],"date-time":"2010-05-10T10:16:11Z","timestamp":1273486571000},"page":"3942-3952","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["p21 Downregulation is an important component of PAX3\/FKHR oncogenicity and its reactivation by HDAC inhibitors enhances combination treatment"],"prefix":"10.1038","volume":"29","author":[{"given":"R M","family":"Hecker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R A","family":"Amstutz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Wachtel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Walter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F K","family":"Niggli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B W","family":"Sch\u00e4fer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,5,10]]},"reference":[{"key":"BFonc2010145_CR1","doi-asserted-by":"publisher","first-page":"3767","DOI":"10.1158\/0008-5472.CAN-07-2447","volume":"68","author":"R Amstutz","year":"2008","unstructured":"Amstutz R, Wachtel M, Troxler H, Kleinert P, Ebauer M, Haneke T et al. (2008). Phosphorylation regulates transcriptional activity of PAX3\/FKHR and reveals novel therapeutic possibilities. Cancer Res 68: 3767\u20133776.","journal-title":"Cancer Res"},{"key":"BFonc2010145_CR2","doi-asserted-by":"publisher","first-page":"6791","DOI":"10.1073\/pnas.95.12.6791","volume":"95","author":"SY Archer","year":"1998","unstructured":"Archer SY, Meng S, Shei A, Hodin RA . (1998). p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells. Proc Natl Acad Sci USA 95: 6791\u20136796.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc2010145_CR3","doi-asserted-by":"publisher","first-page":"4991","DOI":"10.1158\/1078-0432.CCR-04-0210","volume":"10","author":"P Bali","year":"2004","unstructured":"Bali P, George P, Cohen P, Tao J, Guo F, Sigua C et al. (2004). Superior activity of the combination of histone deacetylase inhibitor LAQ824 and the FLT-3 kinase inhibitor PKC412 against human acute myelogenous leukemia cells with mutant FLT-3. Clin Cancer Res 10: 4991\u20134997.","journal-title":"Clin Cancer Res"},{"key":"BFonc2010145_CR4","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1002\/pbc.20650","volume":"47","author":"JW Barlow","year":"2006","unstructured":"Barlow JW, Wiley JC, Mous M, Narendran A, Gee MF, Goldberg M et al. (2006). Differentiation of rhabdomyosarcoma cell lines using retinoic acid. Pediatr Blood Cancer 47: 773\u2013784.","journal-title":"Pediatr Blood Cancer"},{"key":"BFonc2010145_CR5","doi-asserted-by":"publisher","first-page":"13164","DOI":"10.1073\/pnas.93.23.13164","volume":"93","author":"M Bernasconi","year":"1996","unstructured":"Bernasconi M, Remppis A, Fredericks WJ, Rauscher III FJ, Schafer BW . (1996). Induction of apoptosis in rhabdomyosarcoma cells through down-regulation of PAX proteins. Proc Natl Acad Sci USA 93: 13164\u201313169.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc2010145_CR6","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1200\/JCO.2003.06.129","volume":"21","author":"JC Breneman","year":"2003","unstructured":"Breneman JC, Lyden E, Pappo AS, Link MP, Anderson JR, Parham DM et al. (2003). Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma\u2014a report from the Intergroup Rhabdomyosarcoma Study IV. J Clin Oncol 21: 78\u201384.","journal-title":"J Clin Oncol"},{"key":"BFonc2010145_CR7","doi-asserted-by":"publisher","first-page":"8039","DOI":"10.1158\/0008-5472.CAN-08-1712","volume":"68","author":"L Cao","year":"2008","unstructured":"Cao L, Yu Y, Darko I, Currier D, Mayeenuddin LH, Wan X et al. (2008). Addiction to elevated insulin-like growth factor I receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody. Cancer Res 68: 8039\u20138048.","journal-title":"Cancer Res"},{"key":"BFonc2010145_CR8","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1158\/0008-5472.CAN-07-5222","volume":"68","author":"BH Choi","year":"2008","unstructured":"Choi BH, Kim CG, Bae YS, Lim Y, Lee YH, Shin SY . (2008). p21 Waf1\/Cip1 expression by curcumin in U-87MG human glioma cells: role of early growth response-1 expression. Cancer Res 68: 1369\u20131377.","journal-title":"Cancer Res"},{"key":"BFonc2010145_CR9","doi-asserted-by":"publisher","first-page":"7267","DOI":"10.1038\/sj.onc.1210525","volume":"26","author":"M Ebauer","year":"2007","unstructured":"Ebauer M, Wachtel M, Niggli FK, Schafer BW . (2007). Comparative expression profiling identifies an in vivo target gene signature with TFAP2B as a mediator of the survival function of PAX3\/FKHR. Oncogene 26: 7267\u20137281.","journal-title":"Oncogene"},{"key":"BFonc2010145_CR10","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1038\/sj.leu.2404593","volume":"21","author":"Y Furukawa","year":"2007","unstructured":"Furukawa Y, Vu HA, Akutsu M, Odgerel T, Izumi T, Tsunoda S et al. (2007). Divergent cytotoxic effects of PKC412 in combination with conventional antileukemic agents in FLT3 mutation-positive versus -negative leukemia cell lines. Leukemia 21: 1005\u20131014.","journal-title":"Leukemia"},{"key":"BFonc2010145_CR11","doi-asserted-by":"publisher","first-page":"3980","DOI":"10.1158\/0008-5472.CAN-04-3995","volume":"65","author":"AL Gartel","year":"2005","unstructured":"Gartel AL, Radhakrishnan SK . (2005). Lost in transcription: p21 repression, mechanisms, and consequences. Cancer Res 65: 3980\u20133985.","journal-title":"Cancer Res"},{"key":"BFonc2010145_CR12","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1002\/(SICI)1097-0215(19960516)66:4<571::AID-IJC24>3.0.CO;2-9","volume":"66","author":"M Genini","year":"1996","unstructured":"Genini M, Schwalbe P, Scholl FA, Schafer BW . (1996). Isolation of genes differentially expressed in human primary myoblasts and embryonal rhabdomyosarcoma. Int J Cancer 66: 571\u2013577.","journal-title":"Int J Cancer"},{"key":"BFonc2010145_CR13","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.bbrc.2007.11.017","volume":"365","author":"K Kikuchi","year":"2008","unstructured":"Kikuchi K, Tsuchiya K, Otabe O, Gotoh T, Tamura S, Katsumi Y et al. (2008). Effects of PAX3-FKHR on malignant phenotypes in alveolar rhabdomyosarcoma. Biochem Biophys Res Commun 365: 568\u2013574.","journal-title":"Biochem Biophys Res Commun"},{"key":"BFonc2010145_CR14","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/nrg2006","volume":"8","author":"DH Kim","year":"2007","unstructured":"Kim DH, Rossi JJ . (2007). Strategies for silencing human disease using RNA interference. Nat Rev Genet 8: 173\u2013184.","journal-title":"Nat Rev Genet"},{"key":"BFonc2010145_CR15","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1006\/bbrc.2001.4434","volume":"281","author":"JS Kim","year":"2001","unstructured":"Kim JS, Lee S, Lee T, Lee YW, Trepel JB . (2001). Transcriptional activation of p21(WAF1\/CIP1) by apicidin, a novel histone deacetylase inhibitor. Biochem Biophys Res Commun 281: 866\u2013871.","journal-title":"Biochem Biophys Res Commun"},{"key":"BFonc2010145_CR16","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1002\/pbc.21450","volume":"50","author":"EA Kolb","year":"2008","unstructured":"Kolb EA, Gorlick R, Houghton PJ, Morton CL, Lock R, Carol H et al. (2008). Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program. Pediatr Blood Cancer 50: 1190\u20131197.","journal-title":"Pediatr Blood Cancer"},{"key":"BFonc2010145_CR17","doi-asserted-by":"publisher","first-page":"11831","DOI":"10.1073\/pnas.93.21.11831","volume":"93","author":"C Liu","year":"1996","unstructured":"Liu C, Adamson E, Mercola D . (1996). Transcription factor EGR-1 suppresses the growth and transformation of human HT-1080 fibrosarcoma cells by induction of transforming growth factor beta 1. Proc Natl Acad Sci USA 93: 11831\u201311836.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc2010145_CR18","doi-asserted-by":"publisher","first-page":"5340","DOI":"10.1038\/sj.onc.1203038","volume":"18","author":"G Merlino","year":"1999","unstructured":"Merlino G, Helman LJ . (1999). Rhabdomyosarcoma\u2014working out the pathways. Oncogene 18: 5340\u20135348.","journal-title":"Oncogene"},{"key":"BFonc2010145_CR19","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.ctrv.2003.11.001","volume":"30","author":"WH Meyer","year":"2004","unstructured":"Meyer WH, Spunt SL . (2004). Soft tissue sarcomas of childhood. Cancer Treat Rev 30: 269\u2013280.","journal-title":"Cancer Treat Rev"},{"key":"BFonc2010145_CR20","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1038\/onc.2008.371","volume":"28","author":"D Mottet","year":"2009","unstructured":"Mottet D, Pirotte S, Lamour V, Hagedorn M, Javerzat S, Bikfalvi A et al. (2009). HDAC4 represses p21(WAF1\/Cip1) expression in human cancer cells through a Sp1-dependent, p53-independent mechanism. Oncogene 28: 243\u2013256.","journal-title":"Oncogene"},{"key":"BFonc2010145_CR21","doi-asserted-by":"publisher","first-page":"3487","DOI":"10.1200\/JCO.1999.17.11.3487","volume":"17","author":"AS Pappo","year":"1999","unstructured":"Pappo AS, Anderson JR, Crist WM, Wharam MD, Breitfeld PP, Hawkins D et al. (1999). Survival after relapse in children and adolescents with rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study Group. J Clin Oncol 17: 3487\u20133493.","journal-title":"J Clin Oncol"},{"key":"BFonc2010145_CR22","doi-asserted-by":"publisher","first-page":"23360","DOI":"10.1074\/jbc.M300771200","volume":"278","author":"FD Ragione","year":"2003","unstructured":"Ragione FD, Cucciolla V, Criniti V, Indaco S, Borriello A, Zappia V . (2003). p21Cip1 gene expression is modulated by Egr1: a novel regulatory mechanism involved in the resveratrol antiproliferative effect. J Biol Chem 278: 23360\u201323368.","journal-title":"J Biol Chem"},{"key":"BFonc2010145_CR23","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1097\/00043426-200105000-00008","volume":"23","author":"RB Raney","year":"2001","unstructured":"Raney RB, Anderson JR, Barr FG, Donaldson SS, Pappo AS, Qualman SJ et al. (2001). Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of intergroup rhabdomyosarcoma study group experience and rationale for Intergroup Rhabdomyosarcoma Study V. J Pediatr Hematol Oncol 23: 215\u2013220.","journal-title":"J Pediatr Hematol Oncol"},{"key":"BFonc2010145_CR24","doi-asserted-by":"publisher","first-page":"18085","DOI":"10.1073\/pnas.0708910104","volume":"104","author":"W Roeb","year":"2007","unstructured":"Roeb W, Boyer A, Cavenee WK, Arden KC . (2007). PAX3-FOXO1 controls expression of the p57Kip2 cell-cycle regulator through degradation of EGR1. Proc Natl Acad Sci USA 104: 18085\u201318090.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc2010145_CR25","doi-asserted-by":"publisher","first-page":"837","DOI":"10.4161\/cc.7.7.5652","volume":"7","author":"W Roeb","year":"2008","unstructured":"Roeb W, Boyer A, Cavenee WK, Arden KC . (2008). Guilt by association: PAX3-FOXO1 regulates gene expression through selective destabilization of the EGR1 transcription factor. Cell Cycle 7: 837\u2013841.","journal-title":"Cell Cycle"},{"key":"BFonc2010145_CR26","doi-asserted-by":"publisher","first-page":"4058","DOI":"10.1200\/JCO.2001.19.20.4058","volume":"19","author":"LM Smith","year":"2001","unstructured":"Smith LM, Anderson JR, Qualman SJ, Crist WM, Paidas CN, Teot LA et al. (2001). Which patients with microscopic disease and rhabdomyosarcoma experience relapse after therapy? A report from the soft tissue sarcoma committee of the children's oncology group. J Clin Oncol 19: 4058\u20134064.","journal-title":"J Clin Oncol"},{"key":"BFonc2010145_CR27","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1006\/bbrc.1997.7786","volume":"241","author":"Y Sowa","year":"1997","unstructured":"Sowa Y, Orita T, Minamikawa S, Nakano K, Mizuno T, Nomura H et al. (1997). Histone deacetylase inhibitor activates the WAF1\/Cip1 gene promoter through the Sp1 sites. Biochem Biophys Res Commun 241: 142\u2013150.","journal-title":"Biochem Biophys Res Commun"},{"key":"BFonc2010145_CR28","doi-asserted-by":"publisher","first-page":"13548","DOI":"10.1074\/jbc.M510023200","volume":"281","author":"AJ Wilson","year":"2006","unstructured":"Wilson AJ, Byun DS, Popova N, Murray LB, L'Italien K, Sowa Y et al. (2006). Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. J Biol Chem 281: 13548\u201313558.","journal-title":"J Biol Chem"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/onc2010145.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/onc2010145","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/onc2010145.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T17:09:58Z","timestamp":1647882598000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/onc2010145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5,10]]},"references-count":28,"journal-issue":{"issue":"27","published-print":{"date-parts":[[2010,7,8]]}},"alternative-id":["BFonc2010145"],"URL":"https:\/\/doi.org\/10.1038\/onc.2010.145","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,5,10]]},"assertion":[{"value":"2 December 2009","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2010","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2010","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2010","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}